CU-13001
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
CU-13001 is a 15-lipoxygenase (15-LOX, ALOX15) inhibitor which is under development for the treatment of Parkinson's disease. It is taken orally. It is thought that 4-hydroxynonenal (4-HNE), a product of 15-LOX, may be involved in the etiology of Parkinson's disease, and that by inhibiting 4-HNE formation, CU-13001 theoretically may be able to prevent or slow the progression of Parkinson's disease. The drug is under development by Acurex Biosciences. As of September 2024, it is in the preclinical research stage of development for Parkinson's disease. The chemical structure of CU-13001 does not yet appear to have been disclosed.
CU-13001 is a 15-lipoxygenase (15-LOX, ALOX15) inhibitor which is under development for the treatment of Parkinson's disease. It is taken orally. It is thought that 4-hydroxynonenal (4-HNE), a product of 15-LOX, may be involved in the etiology of Parkinson's disease, and that by inhibiting 4-HNE formation, CU-13001 theoretically may be able to prevent or slow the progression of Parkinson's disease. The drug is under development by Acurex Biosciences. As of September 2024, it is in the preclinical research stage of development for Parkinson's disease. The chemical structure of CU-13001 does not yet appear to have been disclosed.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1357355508 under CC BY-SA 4.0; modifications have been made.